Gary Zieziula is out as president of EMD Serono, which gave him the reins for Merck KGaA’s North American operations. The company announced this morning that they’re promoting Rehan Verjee to the president’s office at EMD Serono as well as adding the title role of global head of innovative medicine franchises.
There’s no word about Zieziula’s fate, other than a note that he’ll be staying on through the end of the year to help with the transition.
Verjee has spent the last three years working as a chief marketing and strategy exec for Merck KGaA’s healthcare group, based in Germany. This new role — where he’ll jump to the regional HQ in Rockland, MA — gives him the top biopharma job in the US and Canada, “while maintaining global accountability for the oncology and neurology and immunology franchises.”
“Uniting the leadership of North America with our Global Innovative Medicine Franchises will increasingly put North America at the heart of our strategy,” said Belén Garijo, Member of the Executive Board and CEO Healthcare at Merck KGaA, Darmstadt, Germany. “Rehan’s leadership experience and track record of working across commercial and R&D makes him perfectly suited to ensure we are well positioned to deliver on the promise of our innovative medicine efforts.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.Free Subscription